Santiago Reyna Herrero

Universal Diagnostics S.A. (UDX) is a Spanish in-vitro diagnostics company developing minimally-invasive, blood-based solutions for detecting cancer early when treatment options are more plentiful and survival rates are still high. UDX believes that the best way to fight against cancer is by detecting it early. The UDX diagnostic platform is designed to detect various cancer types, e.g. colorectal, prostate, liver, pancreatic lung, breast cancer (>50% of all new cancer cases p.a.) via one simple blood test. The assays rely on a curated set of proprietary methylation marker panels; a simple blood sample collected as part of a routine check-up, can be processed at a reference laboratory or hospital using standard equipment and then uploaded to the UDX Cloud for final algorithmic analysis. UDX’s first marker panel is a colorectal cancer screening test. The test identifies individuals who need to be referred for colonoscopy. Colorectal cancer is the 3rd most frequent cancer and 2nd deadliest cancer worldwide. The challenge is that colorectal cancer is mostly detected in late stages, with significantly decreased survival rates (11% survival rate in stage IV vs. 85% survival rate in stage I). To develop the test and execute its R&D and operations, UDX partners with international research institutions, hospitals, universities, and biobanks around the globe.

Artax Biopharma is a development-stage biopharmaceutical company dedicated to the development of new therapies for autoimmune and inflammatory diseases. Artax Biopharma is developing the next generation of drugs targeting the interaction between TCR and Nck, which is responsible for T cell activation. Specific control over T cells through TCR, provides the compounds with the potential to become first-in-class immunomodulators for the treatment of a wide range of autoimmune and inflammatory diseases.

Global telemedicine platform that provides access 24/7 to world-class specialists via live on-demand medical video visits. doctors anytime, anywhere®

150 Charter S.L., under the operational name of aBoatTime & BoatGrid provides technology solutions and services for the nautical sector. It is the only complete ecosystem in the world that allows to connect, via Web 2.0 (real-time availability and online payment), end customers and mainstream tourism (touroperators and OTAs) to the fragmented sector of recreational boat chartering. This is possible thanks to the in-house development of: 1) a reservation management software for fleets (BoatGrid.com) – equivalent to SAP for hotels, 2) the only GDS (Global Distribution System) for boats to date – equivalent to what Amadeus is for flights-, and 3) a transactional website for end-clients (aBoatTime.com) – a real-time search and booking engine. Additionally, aBoatTime & BoatGrid offer integration solutions for B2C channels, such as web services or API connections, in-house development of white labels for channel websites, or an agency portal (BG World) for physical agencies and call centre teams. Our goal is to become the standard for the three categories on a world-wide basis, and make boat chartering a holiday alternative to the masses. Customer groups include fleets, travel sellers (tour-operators and travel agencies), and travel buyers (corporations, travel management companies and final clients). Our partners include Booking.com, Viajes El Corte Inglés or Halcón Viajes, amongst others. We have about 2,000 boats under contract in Europe and the Caribbean, an inventory that is constantly growing, and we have recently launched our Premium brochure for high-end yacht rentals (http://boatgrid.com/bgworld/banners/showDocument?nameDocument=premium_ES.pdf). For more info, please visit aBoatTime.com, BoatGrid.com or https://www.youtube.com/c/Aboattime

Atalaya is the first technological solution on the market that manages the investment and equity structure in an integrated and transversal way. We use our own software design that guarantees its independence and is designed by a team of people guided by the purpose of driving the investor towards more efficient operations through technology applied to asset management. We are driven by the desire to generate wealth in the areas in which we operate, helping with our technological development to connect talent opportunities with investment capital. It is the result of the natural evolution of the solid professional careers of its main partners, which come from the fields of venture capital and technological development for e-commerce projects, since we have designed the tool for a market that we know first-hand .

Los family office y las corporates se están convirtiendo en sofisticados inversores en venture capital. Cada día tienen más inquietudes por este sector, invirtiendo directamente en compañías incipientes, pero muchas veces no tienen ni el tiempo ni los recursos para ello. En Keith Ventures ayudamos a estructurar Angel Funds exclusivos para family office y corporates.

Financial Communications and Investor Relations company based in Madrid, Spain.

Universal Diagnostics S.A. (UDX) is a Spanish in-vitro diagnostics company developing minimally-invasive, blood-based solutions for detecting cancer early when treatment options are more plentiful and survival rates are still high. UDX believes that the best way to fight against cancer is by detecting it early. The UDX diagnostic platform is designed to detect various cancer types, e.g. colorectal, prostate, liver, pancreatic lung, breast cancer (>50% of all new cancer cases p.a.) via one simple blood test. The assays rely on a curated set of proprietary methylation marker panels; a simple blood sample collected as part of a routine check-up, can be processed at a reference laboratory or hospital using standard equipment and then uploaded to the UDX Cloud for final algorithmic analysis. UDX’s first marker panel is a colorectal cancer screening test. The test identifies individuals who need to be referred for colonoscopy. Colorectal cancer is the 3rd most frequent cancer and 2nd deadliest cancer worldwide. The challenge is that colorectal cancer is mostly detected in late stages, with significantly decreased survival rates (11% survival rate in stage IV vs. 85% survival rate in stage I). To develop the test and execute its R&D and operations, UDX partners with international research institutions, hospitals, universities, and biobanks around the globe.

Artax Biopharma is a development-stage biopharmaceutical company dedicated to the development of new therapies for autoimmune and inflammatory diseases. Artax Biopharma is developing the next generation of drugs targeting the interaction between TCR and Nck, which is responsible for T cell activation. Specific control over T cells through TCR, provides the compounds with the potential to become first-in-class immunomodulators for the treatment of a wide range of autoimmune and inflammatory diseases.